oblimersen (Bcl-2 antisense)
Jump to navigation
Jump to search
Indications
- adjunctive agent used with dacarbazine for treatment of melanoma
- benefits patients with normal baseline serum LDH levels
Adverse effects
- neutropenia, severe neutropenia (21%)
- thrombocytopenia, severe thrombocytopenia (16%)
- no increase in serious infections or bleeding
Mechanism of action
- 18-base antisense oligonucleotide that downregulates Bcl-2 expression & increases chemotherapy-induced apoptosis
- increases median overall survival, 11.4 vs 9.7 months in patients with normal baseline serum LDH levels
More general terms
References
- ↑ Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10;24(29):4738-45. Epub 2006 Sep 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16966688